Organogenesis, Sandoz deal

Sandoz received exclusive worldwide rights to ORG’s Graftskin manufactured human skin product.

Sandoz initially will make a $5 million equity investment, purchasing 213,950 ORG shares at $23.37. The pharma company could pay an additional $32.5 million to ORG upon milestones, including an additional $10.5 million equity investment. ORG would have 13.4 million shares outstanding after the initial investment. ...